

Supplementary Table 1. Individual patient characteristics

Patient no	Age (yr)	Sex	Disease duration (yr)	K-MMSE	Education (yr)	H&Y stage	UPDRS total	UPDRS I	UPDRS II	UPDRS III	BDI	FSS	Medication
1	71	F	0.5	24	3	2	25	1	7	17	14	2.22	Levodopa/benserazide (100/25 mg) 1.5 tablet three times per day, trihexyphenidyl 1 mg once per day
2	45	M	1.0	30	16	2	31	0	10	21	5	3.11	Ropinirole prolonged release 12 mg once per day, amantadine 100 mg once per day
3	71	M	1.0	30	9	2	26	2	3	21	3	3.33	ropinirole prolonged release 12 mg once per day, amantadine 100 mg twice per day
4	64	M	0.6	26	6	2	39	0	2	37	0	1.33	Levodopa/carbidopa (100/25 mg) 0.75 tablet three times per day, trihexyphenidyl 1 mg once per day, rasagiline 1 mg once per day
5	38	M	0.4	28	12	2	28	3	9	16	14	4.11	
6	54	M	0.5	30	18	2	45	1	9	35	11	4.11	
7	62	M	1.0	26	18	2	29	2	5	22	9	1.33	

K-MMSE: the Korean version of the Mini-Mental State Examination, H&Y stage: Hoehn and Yahr stage, UPDRS: Unified Parkinson's Disease Rating Scale, BDI: Beck Depression Inventory, FSS: Fatigue Severity Scale.